Signals

Recent public signals

Crawlable detail links for recent public signal pages, so search engines can discover more than the live brief.

• FDA panel unanimously endorses Moderna's mRNA seasonal flu vaccine

  Moderna's mRNA seasonal flu vaccine received unanimous backing from an FDA advisory committee, signaling a major step forward for the company. Earlier in the year, the FDA had declined to review the vaccine, but the recent expert endorsement reflects renewed confidence in the shot's safety and efficacy. This development positions Moderna to potentially secure regulatory approval and expand the use of mRNA technology beyond COVID-19 vaccines into seasonal influenza prevention.

• Heart drug biotech Kardigan raises $400 million in upscaled IPO

  In 2026, the biotech sector has seen a surge in large IPOs, with Kardigan leading the way by raising $400 million through an upscaled offering. Specializing in heart drug development, Kardigan's successful IPO contributes to a record year for biotech fundraising, as four companies have each secured $400 million or more in their public offerings. This trend underscores robust investor confidence in biotech innovations targeting cardiovascular diseases.

• UniQure advances US filing for Huntington's gene therapy amid FDA leadership changes

  uniQure is preparing to file its gene therapy for Huntington's disease with the US FDA. This regulatory move coincides with notable leadership changes at the FDA, including the departures of Marty Makary and Vinay Prasad.

• Astellas outlines five-year strategy to offset Xtandi patent cliff with cost savings and innovation

  Astellas is proactively addressing the significant revenue impact expected from the imminent patent expiration of Xtandi, its prostate cancer drug. The company’s CEO, Naoki Okamura, has articulated a five-year plan that combines a substantial cost-savings program with a focus on innovation and sustainable growth rather than simple cost-cutting. This strategy highlights the broader industry challenge of managing patent cliffs while maintaining R&D momentum and market presence.

• Novo Nordisk reports cybersecurity breach affecting clinical trial data

  As cybersecurity threats have increased across industries, biopharma companies have become prominent targets due to their valuable intellectual property and sensitive patient data. Novo Nordisk recently reported a data breach that affected clinical trial information, prompting the company to alert trial participants to stay vigilant. This incident underscores the growing vulnerabilities in pharma data security and the critical need to protect clinical trial data to maintain regulatory compliance and patient trust.

• Novo Nordisk CEO Mike Doustdar calls for greater competitiveness in Big Pharma

  Novo Nordisk CEO Mike Doustdar has highlighted the critical importance of enhancing competitiveness in the pharmaceutical sector. He believes that increased competition will drive faster innovation and better patient outcomes, reflecting a strategic leadership focus on accelerating drug development and R&D productivity within Big Pharma.

• Bay Area biotech SonoThera raises $125 million series B to advance bubble-based gene delivery

  SonoThera has successfully raised $125 million in a series B funding round supported by leading pharmaceutical companies. This infusion of capital is intended to accelerate the clinical development of SonoThera's novel bubble-based gene delivery platform, a technology that has attracted significant interest from the biotech and pharma sectors. The funding underscores the industry's confidence in SonoThera's approach to genetic delivery and positions the company to advance its platform toward clinical trials.

• Medline receives second FDA warning letter over toxic bacteria in products

  Medline, a major medical device distributor, has received a second FDA warning letter since April due to repeated contamination issues involving toxic bacteria in its finished products.

• Akeso’s ivonescimab marks a milestone for Chinese biotech at ASCO 2026

  In 2017, Nanjing Legend Biotech unexpectedly captured global attention at ASCO with Carvykti, a cell therapy showing a 100% objective response rate, effectively putting Chinese biotech on the world map. Building on this momentum, Akeso took center stage at ASCO 2026 when its drug ivonescimab became the first Chinese data set to be featured in a plenary session, underscoring China’s rising influence and competitiveness in global biotech innovation and clinical research.

• Roche pursues new phase 3 trial for oral SERD giredestrant despite first-line breast cancer setback

  Despite a phase 3 failure in first-line breast cancer, Roche continues to see significant potential in its oral SERD drug giredestrant. The company is now launching a new phase 3 trial in the adjuvant setting, signaling a strategic pivot to explore additional therapeutic niches and maintain momentum in breast cancer drug development.

• Ivonescimab shows overall survival benefit in first-line squamous NSCLC but detailed data faces scrutiny

  At ASCO 2026, ivonescimab, a novel PD-1xVEGF bispecific antibody, showed a promising overall survival benefit in first-line treatment of squamous NSCLC. Despite this headline success, detailed data from the combination of ivonescimab with chemotherapy are under critical review by experts, reflecting ongoing scrutiny of its full clinical value and safety profile. This dual targeting approach may represent a new therapeutic option, but further analysis is needed to clarify its role in treatment guidelines.

• GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials

  GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.

• FDA delays decision on Beren Therapeutics’ rare disease drug; Sanofi’s Gaucher drug decision set for November

  The FDA has extended its review of Beren Therapeutics’ rare disease drug candidate, further delaying its potential U.S. market entry. In contrast, the FDA has scheduled a decision for November on Sanofi’s drug for Gaucher disease, providing a clearer near-term regulatory milestone for that asset.

• AbbVie gains FDA approval for rare blood cancer drug from ImmunoGen acquisition

  AbbVie's strategic acquisition of ImmunoGen is yielding significant clinical and commercial benefits, exemplified by the FDA approval of Elahere, a novel antibody-drug conjugate targeting a rare blood cancer. This approval not only expands AbbVie's oncology portfolio but also underscores the growing importance of antibody-drug conjugates in cancer therapy. The milestone supports AbbVie's efforts to diversify its cancer drug offerings and may accelerate patient access to innovative treatments for rare malignancies.

• FDA delays decision on AstraZeneca’s breast cancer drug camizestrant after negative advisory vote

  The FDA has delayed its decision on AstraZeneca’s camizestrant, a breast cancer treatment, after an advisory committee voted against its approval. The regulatory agency is now reviewing further analyses submitted post-vote, reflecting concerns about the inconclusive evidence for this novel therapy. This extension underscores the FDA’s cautious approach to new breast cancer drugs when clinical data remain uncertain.

• Apogee Therapeutics secures $1.3 billion funding from Blackstone to advance eczema drug to phase 3

  Apogee Therapeutics has secured a substantial financing commitment of up to $1.3 billion from Blackstone Life Sciences to propel its anti-IL-13 antibody treatment for eczema into late-stage clinical development. This milestone comes after encouraging new research data strengthened confidence in the drug's potential. The funding will support the initiation of phase 3 trials, positioning Apogee to challenge existing therapies like Dupixent and Ebglyss in the competitive eczema treatment market.

• Cardiovascular biotech Kardigan files for IPO less than two years after launch

  Kardigan, a recently launched cardiovascular-focused biotech, has quickly progressed to filing for an IPO to raise capital for its late-stage drug development programs. This swift transition from startup to public offering highlights both the company's ambition and the current investor enthusiasm for cardiovascular therapeutics. Access to public markets is expected to accelerate funding and development of treatments addressing heart disease, a leading global health concern.

• Eli Lilly expands infectious disease vaccine portfolio with $3.8 billion acquisitions

  Eli Lilly has acquired three biotech companies—Curevo, LimmaTech Biologics, and Vaccine Company—in deals totaling nearly $4 billion.

• Gilead's hepatitis D drug bulevirtide receives FDA approval after earlier manufacturing concerns

  After more than three years since an initial FDA rejection due to manufacturing and delivery concerns, Gilead Sciences' hepatitis D therapy bulevirtide has received accelerated approval in the U.S. This marks the first FDA-approved treatment for hepatitis D, a rare and difficult-to-treat liver disease, expanding therapeutic options and highlighting progress in addressing unmet viral hepatitis needs.

• Data quality and sensitive outcome measures key to advancing oncology and rare disease trials

  Recent advances in biotech clinical trials emphasize that high-quality data is the critical bottleneck for effective AI application in oncology real-world evidence, rather than the algorithms themselves. Concurrently, rare disease trials face unique challenges that demand sensitive clinical outcome assessments to reliably detect treatment effects. AI technologies are increasingly integral to refining these outcome measures, thereby accelerating drug development and regulatory approval processes.

• TROP2-directed ADC plus Keytruda reduces progression risk by 65% in first-line lung cancer

  Ahead of ASCO 2026, new clinical data demonstrate that adding a TROP2-directed ADC to Merck's Keytruda cuts the risk of progression or death by 65% in first-line treatment of PD-L1-positive non-small cell lung cancer. This significant improvement over Keytruda alone highlights the potential of antibody-drug conjugates to boost immunotherapy outcomes and may influence future regulatory and clinical practice landscapes.

• BioMarin plans FDA filing for Voxzogo label expansion after positive phase 3 trial

  BioMarin's recent phase 3 trial results for Voxzogo in treating hypochondroplasia have surpassed the company's expectations, setting the stage for an FDA filing to expand the drug's label. This positive development comes shortly after a phase 3 failure of a competing drug, enhancing Voxzogo's market position in rare dwarfism treatments. The label expansion could broaden patient access and solidify BioMarin's leadership in this niche therapeutic area.

• Eli Lilly's retatrutide shows strong weight loss results in phase 3 obesity trial

  Eli Lilly's retatrutide, a next-generation obesity drug, met the primary weight loss endpoint in a pivotal phase 3 trial. The results show competitive efficacy and tolerability, reinforcing Lilly's leadership in obesity treatment, though some expected stronger outcomes given high market anticipation.

• Infex advances bronchiectasis drug candidate following Insmed's recent trial success

  Following Insmed's recent success in gaining market access for its bronchiectasis drug Brinsupri, Infex Therapeutics is advancing its own non-cystic fibrosis bronchiectasis candidate after positive phase 2a trial data. This progression highlights a competitive and innovative push in the lung disease treatment space, addressing significant unmet medical needs and potentially broadening therapeutic options for patients with bronchiectasis.

• US government deploys experimental antibody from San Diego biotech amid worsening Ebola outbreak

  As the Ebola outbreak in central Africa intensifies with rising fatalities, the US federal government has engaged a small San Diego biotech to supply doses of an experimental antibody treatment. Concurrently, efforts to develop a vaccine are underway to address the escalating epidemic.

• Parabilis files for IPO to advance peptide-based tumor therapies after Regeneron deal

  Parabilis Medicines has filed for an IPO to fund late-stage development of its peptide-based tumor therapies after securing a collaboration deal with Regeneron.

• Bristol Myers and Incyte expand AI use to accelerate drug discovery and development

  Bristol Myers Squibb (BMS) has entered a broad agreement with Anthropic to deploy its AI tool Claude as a shared intelligence platform across BMS's global operations, marking a major enterprise-wide adoption of AI to speed drug research and development....

• Oorja Bio launches with $30 million to develop novel idiopathic pulmonary fibrosis treatment

  Oorja Bio, a new biotech startup based in Houston, has launched with $30 million in funding to develop a novel peptide drug for idiopathic pulmonary fibrosis (IPF), a serious lung disease with limited treatment options. The company, founded by veterans from Acceleron, aims to reverse lung scarring by targeting the underlying biology of IPF. This launch reflects growing interest in innovative fibrosis therapies and addresses an unmet medical need in lung disease treatment.

• Relay Therapeutics reports promising phase 2 data for PI3Kα inhibitor in rare vascular anomalies

  Relay Therapeutics has announced encouraging early phase 2 clinical results for its PI3Kα inhibitor targeting rare vascular anomalies, chronic blood vessel disorders with few effective therapies. The data suggest the drug may offer advantages over current treatments like Novartis’ Vijoice. Relay’s R&D chief remains confident that this therapy can carve out a unique position in this underserved market, highlighting the potential for a new treatment paradigm in these challenging conditions.

• FDA approves AstraZeneca’s new hypertension drug baxdrostat

  AstraZeneca has received FDA approval for baxdrostat, a novel aldosterone synthase inhibitor developed in partnership with CinCor Pharma to treat hypertension.

• Merck and Kelun-Biotech advance sacituzumab tirumotecan for endometrial cancer after positive phase 3 results

  Merck and Kelun-Biotech have achieved positive phase 3 trial results for their TROP2-targeting antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) in certain endometrial cancer patients.

• Regeneron's LAG-3 inhibitor fails phase 3 melanoma trial, marking second late-stage setback

  Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo in melanoma failed to meet its primary endpoint, not significantly outperforming Keytruda. This unexpected result represents the company's second major late-stage clinical failure within a year and led to a sharp decline in market value.

• FDA faces potential leadership departures following commissioner Makary's resignation

  With the resignation of FDA commissioner Marty Makary now official, attention turns to the possibility of further leadership changes at the agency. Reports reveal that Tracy Beth Hoeg, the chief of the Center for Drug Evaluation and Research (CDER), may be heading out the door as well. These potential departures mark a notable shift in the FDA's top regulatory ranks, which could impact ongoing drug evaluation and approval processes.

• FDA places full clinical hold on Aardvark's phase 3 Prader-Willi syndrome trial

  Aardvark Therapeutics faces a major setback as the FDA has placed a full clinical hold on its phase 3 trial for a Prader-Willi syndrome treatment due to safety concerns. The company is now planning to unblind the trial data early, an unusual step that may prompt a comprehensive reassessment of its drug development strategy. This development highlights the challenges in advancing treatments for Prader-Willi syndrome, a condition with significant unmet medical needs.

• Takeda announces 4,500 job cuts amid major pharma deals and industry leadership campaigns

  Takeda plans to cut 4,500 jobs in fiscal 2026 as part of a restructuring effort. Meanwhile, Bristol-Myers Squibb and Hengrui signed a significant deal worth up to $15.2 billion. Daiichi Sankyo aims to become a top-5 global oncology player, expanding beyond antibody-drug conjugates.

• Biogen advances tau-targeting Alzheimer's drug despite phase 2 trial setback

  Biogen is moving forward with late-stage development of its tau-targeting Alzheimer's drug BIIB080 despite a phase 2 trial missing its primary endpoint.

• Biopharma leaders support Richard Pazdur as next FDA commissioner amid leadership vacancy

  The FDA is currently without a commissioner after Marty Makary, M.D., revealed his intention to step down. This development has prompted widespread support from biopharma leaders for Richard Pazdur, M.D., who previously served as the FDA's top drug regulator. They view Pazdur as the natural choice for President Donald Trump to appoint as the next FDA commissioner, aiming to restore stable leadership to the agency.

• Regenxbio’s Duchenne gene therapy meets primary endpoint in pivotal phase 3 trial

  Regenxbio has achieved a significant milestone by meeting the primary endpoint in its pivotal phase 3 trial for Duchenne muscular dystrophy gene therapy.

• FDA approves BeOne's Beqalzi and Taiho's therapies for blood cancers

  BeOne Medicines has secured FDA approval for Beqalzi (sonrotoclax), a first-in-class BCL-2 inhibitor for mantle cell lymphoma, distinguishing itself ahead of potential competition with Venclexta, the current market leader. This approval represents a significant advancement in targeted therapies for blood cancers. Concurrently, Taiho has also received FDA approvals for its blood cancer treatments, underscoring ongoing innovation and expanded options in hematologic oncology.

• FDA commissioner Marty Makary resigns after turbulent tenure

  Marty Makary, M.D., has resigned as FDA commissioner, ending a brief and tumultuous period marked by leadership upheaval, political pressure, and public disputes with drugmakers. His departure leaves the agency with temporary directors in key roles and uncertainty about the future of newly implemented policies.

• Valneva plans up to 15% workforce reduction amid cost-cutting efforts

  Valneva, a French vaccine developer, is responding to financial pressures caused by declining travel and vaccine demand by planning a workforce reduction of up to 15%. This cost-cutting measure highlights the challenges faced by vaccine companies in the current market environment and may impact the company's operational capacity and development timelines.

• Isomorphic Labs secures $2.1 billion to advance AI-driven drug discovery

  Isomorphic Labs has successfully closed a $2.1 billion Series B funding round, underscoring the growing investor enthusiasm for AI-driven drug discovery platforms. As a spinout from Alphabet, the company aims to harness artificial intelligence to revolutionize drug design and development, potentially speeding up the creation of new therapies. This milestone reflects the broader industry trend of integrating AI technologies into pharmaceutical R&D to enhance efficiency and innovation.

• GSK partners with Sino Biopharmaceutical to expand hepatitis B drug access in China

  GSK is advancing its strategy to increase access to its hepatitis B drug bepirovirsen in China by partnering with Sino Biopharmaceutical. This marketing agreement reflects a broader trend of GSK collaborating with local Chinese firms to facilitate the rollout of key therapies in the rapidly evolving Chinese biotech market. Such partnerships are intended to accelerate patient access to innovative treatments and strengthen GSK's presence in a significant global market for hepatitis B therapies.

• Daiichi Sankyo outlines plan to become top five global oncology player by 2035

  Daiichi Sankyo is pursuing a strategic transformation to establish itself as a leading global oncology company by 2035. Central to this plan is its expertise in antibody-drug conjugates, a key innovation area in cancer treatment. To enable this growth, the company is implementing a $1.3 billion cost optimization initiative aimed at improving operational efficiency and supporting sustained investment in oncology R&D and drug development.

• Inhibrx’s OX40 agonist doubles Keytruda response rate in midphase trial

  Inhibrx Biosciences has demonstrated encouraging midphase clinical trial results by combining its OX40 agonist with Merck & Co.’s Keytruda, doubling the response rate in cancer patients. This efficacy signal highlights the potential of Inhibrx’s drug to enhance immuno-oncology treatment and has reportedly drawn Merck’s interest, signaling possible strategic collaboration or acquisition. The data supports advancing the program in drug development, reflecting ongoing innovation in cancer therapies.

• President Trump approves plan to fire FDA Commissioner Marty Makary

  President Donald Trump has authorized a plan to dismiss FDA Commissioner Marty Makary, M.D., signaling a significant leadership change at the agency responsible for drug approvals and regulatory oversight. The decision, reported by The Wall Street Journal and covered by multiple biotech and pharma news outlets, may impact the FDA's direction and policies moving forward.

• Daiichi Sankyo faces $610 million profit hit due to antibody-drug conjugate manufacturing issues

  Daiichi Sankyo's financial outlook for fiscal year 2025 has been adversely affected by a substantial $610 million profit hit related to its antibody-drug conjugate manufacturing approach. The company’s precautionary strategy in ADC production has resulted in significant losses, driving the firm into negative earnings territory. This development underscores the complexities and risks associated with ADC manufacturing in biotech drug development and its direct impact on company profitability.

• Analysts cut sales forecasts for enGene and note Sarepta's gene therapy sales decline

  Leerink Partners analysts have reduced their sales forecast for enGene Therapeutics' bladder cancer candidate following phase 2 data that weakened confidence in its ability to compete with rivals like Johnson & Johnson.

• Odyssey Therapeutics completes upsized IPO to fund autoimmune and inflammatory drug pipeline

  Odyssey Therapeutics successfully launched its initial public offering after previously withdrawing its filing last year. The biotech raised between $279 million and $304 million in an upsized IPO to support development of its immune drug candidates targeting autoimmune and inflammatory diseases.

• Angelini to acquire Catalyst Pharmaceuticals in $4.1B deal to expand U.S. rare neuro drug presence

  Italian pharmaceutical company Angelini Pharma is set to acquire Catalyst Pharmaceuticals, a specialist in rare diseases, for $4.1 billion. This acquisition provides Angelini with access to Catalyst's portfolio of medicines approved for central nervous system (CNS) disorders and expands its presence in the lucrative U.S. market. Notably, the deal includes Catalyst's potential blockbuster drug Firdapse, strengthening Angelini's position in rare neurological therapeutics.

• FDA reconsiders previously rejected T-cell therapy, raising hopes for uniQure gene therapy

  The FDA has agreed to reconsider a T-cell therapy that was surprisingly rejected in January due to concerns over its single-arm trial design. This development could renew investor optimism for a potential reversal in the regulatory fate of uniQure's high-profile gene therapy, which faces similar trial challenges.

• FDA pilots one-day inspectional assessments to enhance oversight efficiency

  The FDA has launched a pilot program introducing one-day inspectional assessments aimed at making its inspection resources more targeted and efficient. This initiative complements traditional site visits by enabling the agency to better deploy its on-site inspection capabilities and strengthen oversight.

• Bayer to acquire Perfuse in deal worth up to $2.45 billion to expand eye disease pipeline

  Bayer is acquiring Perfuse, a biotech developing an implant for eye diseases, in a deal valued at up to $2.45 billion including milestones.

• FDA blocks publication of studies finding COVID and shingles vaccines safe

  Recent studies conducted by FDA scientists found COVID-19 vaccines and GSK's shingles vaccine Shringrix to be safe and effective, with serious side effects being rare.

• CellCentric secures $220M Series D to advance multiple myeloma drug through late-stage trials

  CellCentric has raised $220 million in a Series D funding round led by Venrock to support ongoing Phase 2 and planned Phase 3 clinical trials of inobrodib, an oral drug targeting multiple myeloma.

• Viridian Therapeutics posts positive phase 3 results for thyroid eye disease drug

  Viridian Therapeutics has achieved a significant milestone with its anti-IGF-1R antibody in a second phase 3 trial for chronic thyroid eye disease, meeting the primary endpoint. This success follows earlier mixed results and positions Viridian as a strong competitor to Amgen's established Tepezza treatment, especially for patients with chronic manifestations of the disease. The company is preparing to submit for FDA approval next year, potentially expanding treatment options in a market dominated by Tepezza.

• Sanofi invests $294 million to expand AI center of excellence in Toronto

  French pharmaceutical company Sanofi is accelerating its artificial intelligence initiatives with a $294 million investment to expand its global AI center of excellence located in Toronto. The expansion builds on the digital infrastructure the company developed at this Canadian hub over the past four years. This move reflects Sanofi's commitment to integrating advanced AI technologies into its drug development and research processes, potentially improving efficiency and innovation in biotech R&D.

• Strand Therapeutics CEO urges US to modernize early-stage clinical trial regulations

  Jake Becraft, Ph.D., CEO of Strand Therapeutics, highlights the critical need for the US to update its regulatory framework for early-stage clinical trials.

• Celcuity’s gedatolisib shows positive phase 3 results in breast cancer, advancing FDA filings

  Celcuity’s pan-PI3K/mTOR inhibitor gedatolisib has met the primary endpoint in the phase 3 Viktoria-1 trial for HR+ metastatic breast cancer, demonstrating significantly longer progression-free survival compared to Novartis’ Piqray in PIK3CA-mutant patients.

• UCB acquires Candid Therapeutics for $2 billion to expand autoimmune T-cell engager portfolio

  UCB is acquiring Candid Therapeutics for $2 billion upfront, gaining access to a portfolio of bispecific antibody drugs targeting autoimmune diseases.

• FDA approves Pfizer and Arvinas' novel breast cancer drug Veppanu

  Veppanu, developed by Arvinas and Pfizer, received early FDA approval as a first-in-class breast cancer treatment. This milestone expands therapeutic options for patients with certain breast cancers. However, Pfizer and Arvinas plan to partner with another company for commercialization, indicating ongoing strategic efforts post-approval.

• Summit Therapeutics shares fall after surprise interim miss in ivonescimab trial

  Summit Therapeutics experienced a sharp decline in share price following an unexpected interim analysis miss in its Harmoni-3 trial of ivonescimab, a PD-1xVEGF bispecific antibody.

• NICE backs UCB’s drug for uncontrolled gMG; UniQure seeks UK approval for Huntington’s gene therapy

  The UK’s NICE has recommended UCB’s drug as the first therapy for uncontrolled generalized myasthenia gravis (gMG), marking a significant treatment advance.

• Avalyn Pharma raises $300 million in oversized IPO to advance inhaled respiratory drugs

  Avalyn Pharma has completed an oversized initial public offering, raising $300 million to fund the late-stage development of its inhaled reformulations of approved respiratory drugs. The biotech's successful IPO reflects strong investor interest in respiratory drug innovation and will enable Avalyn to advance clinical trials for these potentially improved therapies.

• Advances in CAR-T cell therapies highlight allogeneic and in vivo approaches

  Recent research demonstrates promising developments in CAR-T cell therapies, including CRISPR-engineered allogeneic CAR-T cells targeting solid tumors and a novel modular CAR platform enabling antibody-guided retargeting.

• AstraZeneca resumes $300 million UK investment after pricing dispute pause

  AstraZeneca has reversed its decision to freeze a $300 million investment program in the UK, restarting projects at two sites after a seven-month pause caused by frustrations over national drug pricing negotiations.

• Teva acquires Emalex Biosciences for $700M to advance near-approval Tourette drug

  Teva Pharmaceuticals has struck a $700 million upfront deal to acquire Emalex Biosciences, aiming to advance Emalex's experimental Tourette syndrome drug candidate nearing approval. This acquisition represents Teva's largest deal in ten years and is seen by analysts as a strategic fit that complements Teva's existing neurology business. The move positions Teva to strengthen its pipeline with a promising treatment for Tourette syndrome, potentially expanding its footprint in neurological disorders.

• Chiesi to acquire KalVista and its hereditary angioedema drug Ekterly in $1.9 billion deal

  Chiesi Group is expanding its rare disease portfolio by acquiring KalVista Pharmaceuticals for $1.9 billion. This deal includes KalVista's oral hereditary angioedema drug Ekterly, which is approaching its one-year mark since FDA approval. The acquisition underscores the pharmaceutical industry's increasing focus on innovative oral therapies for rare diseases like HAE and marks Chiesi's fifth biotech acquisition in a short period, signaling strategic growth in this sector.

• FDA pilots real-time clinical trial data sharing with Amgen and AstraZeneca

  The FDA is testing a new approach to clinical trials by collaborating with Amgen and AstraZeneca to share study data in real time as it is collected. This pilot aims to accelerate drug development and regulatory review.

• FDA raises concerns over AstraZeneca’s camizestrant and Truqap ahead of advisory meeting

  The FDA has released briefing documents outlining its concerns regarding AstraZeneca’s cancer therapies camizestrant and Truqap. This release precedes an advisory committee meeting scheduled to review these drugs, the first such meeting in about nine months. The FDA’s detailed concerns focus on the safety and efficacy data submitted by AstraZeneca, signaling a critical regulatory evaluation phase for these candidates.

• FDA launches initiative for real-time clinical trial data access

  The FDA has announced a major initiative to implement real-time clinical trials (RTCT), enabling its reviewers to access clinical trial data as it is generated.

• Boehringer and Zealand’s dual-acting obesity drug shows significant weight loss in Phase 3 trial

  Survodutide, a dual-acting obesity drug developed by Boehringer Ingelheim and Zealand Pharma, demonstrated a 16.6% weight loss in a Phase 3 clinical trial. Analysts compared its efficacy to Wegovy and noted potential benefits in preserving muscle mass during weight loss.

• FDA alleges data manipulation in Amgen drug; Erasca's promising RAS drug faces market skepticism

  The FDA accused the original developer of Amgen's Tavneos of hiding and altering study data, raising regulatory concerns. Meanwhile, Erasca published phase 1 data for its pan-RAS drug showing a 'home run' profile, but the stock dropped 42% amid investor skepticism.

• Eli Lilly partners with AI startup Profluent to develop gene-editing recombinases

  Eli Lilly has entered a $2.2 billion collaboration with AI startup Profluent to develop AI-designed recombinases aimed at treating diseases with significant unmet medical needs.

• Coultreon Biopharma raises $125 million to advance immune drug licensed from Galapagos

  Coultreon Biopharma, formerly Onco3R Therapeutics, secured $125 million in Series A funding to develop an oral immune drug licensed from Galapagos. The Belgian biotech, launched in 2025 to develop deprioritized Galapagos assets, aims to test the drug's potential across multiple immunological diseases.

• Eli Lilly acquires Ajax Therapeutics for next-generation myelofibrosis JAK inhibitor

  Eli Lilly continues its strategic expansion in biotech by acquiring Ajax Therapeutics for up to $2.3 billion. Ajax's clinical-stage type 2 JAK-2 inhibitor targets myelofibrosis, aiming to overcome the shortcomings of current JAK inhibitors. This acquisition strengthens Lilly's hematology pipeline and reflects the company's focus on next-generation targeted therapies for unmet medical needs.

• Oruka’s long-acting psoriasis drug shows strong phase 2a results, raising blockbuster potential

  Oruka Therapeutics reported that its long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, outperforming AbbVie’s Skyrizi in potency and offering less frequent dosing. Jefferies analysts forecast the drug could generate up to $10 billion in sales.

• Ligand Pharmaceuticals acquires biotech royalty aggregator Xoma Royalty

  After an active period of dealmaking in the previous year, Xoma Royalty, a biotech royalty aggregator, is now being acquired by its peer Ligand Pharmaceuticals. This transaction brings together two significant entities in the biotech royalty aggregation space, which may influence the management of royalty streams and funding mechanisms within the biotech industry.

• Astellas refocuses pipeline amid gene therapy setbacks and explores cell therapy potential

  Astellas Pharma has recently streamlined its early-stage pipeline by discontinuing two phase 1 candidates and halting development of a challenging rare disease gene therapy.

• Intellia files for FDA approval after successful phase 3 trial of in vivo CRISPR therapy

  Intellia Therapeutics announced that its in vivo gene editing therapy, lonvoguran ziclumeran, met the primary endpoint in a phase 3 trial targeting hereditary angioedema.

• FDA awards three priority review vouchers to psychedelic drug developers

  The FDA's recent awarding of three national priority review vouchers to Compass Pathways, the Usona Institute, and Transcend Therapeutics underscores the agency's commitment to fast-tracking psychedelic therapies. This move reflects ongoing momentum in psychedelic R&D and regulatory prioritization, a trend initiated under the Trump administration. The involvement of major players like Otsuka, acquiring Transcend Therapeutics, signals consolidation and growing industry interest in this emerging sector.

• FDA declines approval of AbbVie's new Botox product over manufacturing concerns

  The FDA has declined to approve AbbVie's follow-up product to Botox, citing manufacturing-related issues. This regulatory setback aligns with the agency's recent rejection of two new products from AbbVie and Grace Therapeutics due to similar manufacturing concerns.

• Avalyn Pharma plans $181.8M IPO to fund phase 3 trials of inhaled respiratory drugs

  Avalyn Pharma is preparing for an initial public offering to secure around $181.8 million in funding. The biotech company plans to use the capital to advance its inhaled formulations of existing approved respiratory drugs into phase 3 clinical trials. This strategic step aims to bring reformulated respiratory therapies closer to market, potentially enhancing treatment efficacy and patient outcomes in respiratory care.

• FDA approves first gene therapy for genetic hearing loss under priority voucher program

  The FDA has approved Otarmeni (lunsotogene parvec-cwha), developed by Regeneron, as the first-ever gene therapy to treat a rare inherited form of hearing loss.

• AbbVie to invest $1.4 billion in new manufacturing campus in North Carolina

  Coverage discusses speculative scenarios around ~$1.4B; treat as market chatter and see linked sources.

• Moderna begins pivotal trial for mRNA bird flu vaccine after funding setback

  Moderna's mRNA bird flu vaccine program experienced a funding setback when the US Department of Health and Human Services decided to abandon mRNA research funding. However, the initiative was revived by a coalition involving public and private partners. As a result, Moderna has now launched a pivotal late-stage clinical trial for its H5N1 bird flu vaccine. This trial represents a critical step toward potential regulatory approval and availability of the vaccine.

• Merck deepens AI investment with $1 billion Google Cloud deal amid pharma industry shifts

  Merck is advancing its artificial intelligence capabilities through a $1 billion enterprise agreement with Google Cloud, signaling a strong commitment to AI-driven drug development despite ongoing industry challenges such as layoffs and mergers.

• Flagship Pioneering launches Serif to develop novel modified DNA therapies

  Serif, a biotech startup launched by Flagship Pioneering, is developing a new class of genetic medicines based on chemically modified DNA. This approach seeks to combine the strengths of messenger RNA and gene therapy by introducing chemical tweaks and partnering with proteins to create novel therapeutics. Serif's innovation reflects growing momentum in genetic medicine, supported by significant funding and advances in DNA modification technologies.

• Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal for in vivo cell therapy

  Eli Lilly is expanding its in vivo cell therapy portfolio with the acquisition of Kelonia Therapeutics, a company developing a phase 1-stage CAR-T therapy targeting multiple myeloma. The deal, valued at up to $7 billion with $3.25 billion paid upfront, represents Lilly's second acquisition in this space this year. This move underscores Lilly's commitment to advancing innovative cancer treatments through early-stage cell therapy development.

• Trump orders FDA to fast-track reviews of psychedelic drugs for mental illness treatment

  President Donald Trump has directed the FDA to prioritize reviews of psychedelic drugs to expedite access to treatments for serious mental illnesses. This move aims to clear regulatory barriers and accelerate drug development in this emerging therapeutic area.

• FDA meets first-year goals to reduce animal testing in drug development

  The FDA announced it has achieved the first-year objectives of its roadmap aimed at reducing animal testing in drug development by launching key initiatives to replace animal studies with better alternatives.

• CDMO partnerships and early coordination accelerate complex drug development

  Leaders from Axplora and experts like Doug Ahrens of Thermo Fisher Scientific highlight that agile partnerships with CDMOs and early coordination across functions, development phases, and partners are key drivers of speed in complex drug development. By fostering collaboration early, companies can reduce risks and streamline processes, ultimately accelerating the delivery of new therapies to patients.

• UCB expands into regenerative medicine with Neurona acquisition for epilepsy cell therapy

  Belgian biopharma UCB announced an agreement to acquire Neurona Therapeutics for up to $1.2 billion.

• OpenAI launches GPT-Rosalind AI to accelerate drug discovery and biology research

  OpenAI has unveiled GPT-Rosalind, an AI model tailored specifically for drug discovery and biology research. The launch comes shortly after OpenAI's partnership with Novo Nordisk, highlighting a strategic focus on biotech innovation. Multiple biotech firms have begun adopting GPT-Rosalind, reflecting growing industry interest in AI-driven tools to accelerate translational medicine and drug development.

• Kailera Therapeutics sets new record with $625 million IPO to fund obesity drug pipeline

  Kailera Therapeutics has made headlines by completing a record-breaking $625 million IPO, an upsized offering that sets a new standard in biotech fundraising. The capital raised is earmarked to advance its pipeline focused on obesity therapeutics, reflecting the growing market and clinical interest in addressing obesity through novel drug development.

• Researchers question efficacy of anti-amyloid Alzheimer's drugs despite some FDA approvals

  Despite achieving some FDA approvals, the anti-amyloid drug class for Alzheimer's disease faces growing scrutiny from researchers who are evaluating the collective clinical trial outcomes. The emerging consensus paints a disappointing picture regarding the efficacy of these therapies, with many candidates failing and the approved drugs showing limited or negligible clinical benefits. This critical reassessment challenges the therapeutic value of targeting amyloid in Alzheimer's treatment.

• Lilly confirms Foundayo’s heart safety in ACHIEVE-4 trial supporting diabetes approval

  Eli Lilly has confirmed the cardiovascular safety of its obesity drug Foundayo in the ACHIEVE-4 clinical trial. These positive safety results come amid FDA scrutiny and support Lilly's plans to seek regulatory approval for Foundayo as a diabetes treatment.

• MeiraGTx reacquires eye disease gene therapy after J&J phase 3 failure

  Johnson & Johnson has returned full rights to the rare eye disease gene therapy botaretigene sparoparvovec (bota-vec) to MeiraGTx following a phase 3 clinical trial failure. MeiraGTx reacquired the asset for a $25 million upfront payment.

• Roche launches new clinical trial for Duchenne gene therapy Elevidys after European rejection

  After the European Medicines Agency rejected Elevidys, a gene therapy for Duchenne muscular dystrophy, Roche is launching a new clinical trial to generate further data. This effort aims to address regulatory concerns and support approval efforts in Europe and beyond. Roche, which owns rights to Elevidys outside the U.S., is focusing on rigorous clinical evidence rather than advocacy to overcome the regulatory hurdles and expand treatment options for patients with this rare disease.

• Terremoto Biosciences raises $108 million to advance AKT-targeting drug candidates

  Terremoto Biosciences, a California biotech company focused on developing covalent inhibitors targeting the AKT pathway, announced a $108 million Series C funding round. The proceeds will fuel ongoing clinical trials, including a Phase 1 therapy already in testing, and support the advancement of an additional candidate expected to enter clinical trials within the year. This capital injection aims to broaden the company's drug development efforts against AKT1, a significant target in cancer treatment.

• Travere wins FDA approval for Filspari in rare kidney disease FSGS

  Travere Therapeutics has received FDA approval for Filspari to treat focal segmental glomerulosclerosis (FSGS), marking a significant milestone in addressing this rare kidney disease.

• Novo Nordisk to deploy OpenAI technology across R&D, manufacturing, and corporate functions

  Novo Nordisk is adopting OpenAI's artificial intelligence technology to enhance its drug development and operational processes. The AI will be used to analyze complex datasets, enabling the company to shorten R&D timelines. Additionally, the technology will be applied to improve efficiencies in manufacturing and corporate functions, reflecting a strategic move toward digital transformation across multiple business areas.

• Eli Lilly acquires CrossBridge Bio to expand dual-payload ADC pipeline

  Eli Lilly has acquired Houston-based CrossBridge Bio in a deal worth up to $300 million to enhance its antibody-drug conjugate (ADC) portfolio.

• FDA urges over 2,200 sponsors to disclose clinical trial results amid reporting gaps

  The FDA has reminded more than 2,200 drug companies, medical device manufacturers, and researchers of their obligation to submit clinical trial results to ClinicalTrials.gov.

• Revolution’s RAS inhibitor nearly doubles survival in phase 3 pancreatic cancer trial

  Revolution’s RAS inhibitor has demonstrated a significant survival benefit in a phase 3 trial for pancreatic cancer, a disease with historically poor outcomes. Analysts have described the results as a potential game changer, nearly doubling survival rates in this difficult-to-treat tumor type.

• Spyre Therapeutics reports promising phase 2 results for ulcerative colitis drug

  Spyre Therapeutics announced positive phase 2 trial results for its monoclonal antibody therapy targeting ulcerative colitis. The drug demonstrated remission rates suggesting a "best-in-class" profile, with the company positioning it as a potential competitor to Takeda's blockbuster Entyvio.

• FDA rejects Replimune's melanoma therapy for the second time

  Replimune has faced a major regulatory hurdle as the FDA rejected its melanoma immunotherapy candidate RP1 for the second time. The initial refusal occurred in July of the previous year, and despite efforts to address the agency's concerns, the resubmitted application was again declined. This repeated rejection highlights the challenges Replimune faces in advancing RP1 through the regulatory process and may impact the therapy's development timeline and market prospects.

• Ideaya and Servier’s PKC inhibitor meets primary endpoint in uveal melanoma trial

  The phase 2/3 trial success of Ideaya and Servier’s PKC inhibitor for uveal melanoma marks a significant milestone in drug development for this rare cancer. Meeting the primary endpoint is critical for advancing regulatory approval, and the companies plan to file for accelerated FDA approval later in 2026. This progress highlights the potential of PKC inhibitors in addressing unmet medical needs in oncology and could influence ongoing biotech investment and development strategies.

• FDA rejects Replimune's melanoma drug RP1 for the second time

  Replimune's melanoma drug candidate RP1 has faced a second rejection from the FDA. The agency declined the resubmitted application because Replimune failed to adequately address concerns related to the clinical study results. This repeated refusal underscores the regulatory hurdles in gaining approval for RP1 and reflects broader debates about flexibility in drug evaluation standards.

• Oricell Therapeutics raises over $100 million ahead of IPO to develop CAR-T therapy for liver cancer

  Oricell Therapeutics, a Chinese biotech company specializing in CAR-T therapies, has completed a significant funding round exceeding $100 million as it prepares for an initial public offering. The company is advancing a novel cell therapy aimed at solid tumors, particularly liver cancer, which currently lacks CAR-T treatment options. This financing milestone supports Oricell's clinical development efforts and positions it to potentially introduce a pioneering therapy for liver cancer patients.

• Top biotech deals in March 2026 and leading pharma R&D budgets for 2025

  March 2026 marked a busy period for biotech dealmaking, with numerous high-profile transactions spanning small molecules and antibody therapeutics, reflecting ongoing consolidation and strategic repositioning in the sector. Meanwhile, analysis of 2025 pharmaceutical R&D budgets reveals which companies are leading investment in drug development and how their priorities have evolved, providing insight into the innovation landscape shaping future therapies.

• Avalyn Pharma files IPO to fund phase 3 trials of inhaled lung disease drugs

  Coverage discusses speculative scenarios; treat as market chatter and see linked sources.

• Jeito Capital closes record $1.2 billion fund for European biopharma

  Jeito Capital has secured $1.2 billion in funding, the largest raise ever for an independent European biopharma-focused venture fund. This new capital will back 15 to 20 clinical-stage biopharma companies, highlighting strong investor confidence in European biotech innovation and positioning Jeito as a key player in advancing clinical-stage drug development across the region.

• Gilead acquires Tubulis to enhance oncology ADC pipeline with $5 billion deal

  Gilead Sciences has agreed to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments.

• Sanofi’s bispecific drug lunsekimig shows mixed phase 2 results in respiratory and eczema trials

  Sanofi's bispecific antibody lunsekimig, targeting TSLP and IL-13, demonstrated positive phase 2 clinical trial results in asthma and nasal polyps but failed to meet endpoints in a separate eczema study.

• Takeda ends Denali partnership amid restructuring and FDA proposes trial reforms

  Takeda has terminated its neurodegenerative disease partnership with Denali Therapeutics as part of a major corporate restructuring involving significant layoffs.

• Anthropic expands into biopharma with AI startup acquisition amid rising interest in augmented intelligence

  Anthropic, a leading AI company, has acquired stealth AI startup Coefficient Bio for $400 million in stock, marking a significant move into healthcare.

• Neurocrine Biosciences to acquire Soleno Therapeutics and its Prader-Willi drug in $2.9 billion deal

  Neurocrine Biosciences is making its largest acquisition to date by purchasing Soleno Therapeutics for $2.9 billion.

• Novavax shifts to partnership model, licensing Matrix-M adjuvant to Sanofi and Pfizer

  Novavax has restructured by shedding costly commercial infrastructure and is now focusing on a partnership strategy.

• Biopharma sees surge in M&A activity with $29 billion in deals in late March 2026

  In the final two weeks of March 2026, biopharma companies executed seven major transactions totaling $29 billion. This flurry of dealmaking confirms that the robust M&A momentum observed in the fourth quarter of 2025 is continuing into 2026, setting the stage for a highly active year in biopharma mergers and acquisitions. The surge reflects strong investor confidence and strategic repositioning within the sector, with significant capital flowing into drug development and R&D funding.

• Trump finalizes 100% tariffs on US pharma imports with some exemptions

  Former President Trump has finalized tariffs of up to 100% on certain pharmaceutical imports under Section 232 national security provisions. However, a range of drugs are exempted from these levies, which analysts say limits the overall threat to the pharmaceutical sector.

• Immunovant’s FcRn inhibitor fails phase 3 trials for thyroid eye disease

  Immunovant’s first-generation FcRn inhibitor failed two pivotal phase 3 clinical trials targeting thyroid eye disease, effectively ending prospects for the drug's commercialization.

• FDA approves Lilly's oral weight-loss pill Foundayo, intensifying competition with Novo Nordisk

  The FDA has approved Eli Lilly's oral GLP-1 weight-loss medication Foundayo (orforglipron), marking it as the second pill of its kind after Novo Nordisk's Wegovy. Foundayo's approval challenges Wegovy's four-month market lead, sparking a debate between the two companies over efficacy and convenience.

• FDA approves Eli Lilly’s oral weight-loss pill Foundayo, intensifying competition with Novo Nordisk

  The FDA has approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 receptor agonist for weight loss, marking the second GLP-1 pill to reach the US market after Novo Nordisk’s Wegovy.

• FDA approves Lilly’s GLP-1 pill as first new molecular entity under national priority voucher program

  The FDA has approved Foundayo (orforglipron), Lilly’s GLP-1 receptor agonist pill, marking the first new molecular entity cleared under the Commissioner's National Priority Voucher (CNPV) pilot program.

• Biotech layoffs show signs of slowing, but peak remains uncertain

  The biotech sector experienced a wave of layoffs in recent periods, raising concerns about industry stability. However, new reports from Fierce Biotech and Fierce Pharma reveal that layoffs have begun to slow down in the first quarter of 2026. This deceleration hints at a possible easing of workforce reductions, though experts caution that it is premature to declare the peak of layoffs behind us. The evolving data underscores ongoing uncertainty but offers a cautiously optimistic view of biotech employment trends.

• FDA delays decision on Orca Bio's blood cancer cell therapy to July 6

  Orca Bio's promising cell therapy for blood cancers, Orca-T, faces a regulatory delay as the FDA extends its review timeline by three months to July 6. This extension comes after Orca Bio provided additional CMC-related data, which the FDA requires to complete its assessment. The delay underscores the complexities involved in evaluating novel cell therapies and the importance of comprehensive manufacturing data to ensure safety and efficacy before approval.

• FDA flags serious liver injury concerns linked to Amgen's Tavneos

  Recent FDA reports have highlighted significant safety concerns regarding Amgen's Tavneos, a drug linked to 76 cases of liver injury, including eight deaths. These findings underscore the importance of monitoring Tavneos' hepatic safety profile and may impact its clinical use and regulatory status.

• Merck partners with Infinimmune in $838 million antibody discovery collaboration

  Merck has entered a research and development collaboration with antibody discovery startup Infinimmune, committing up to $838 million to identify immune cell-directed antibodies for multiple undisclosed targets.

• Lilly expands AI drug discovery partnership and seeks UK pricing deal to support investments

  Coverage discusses speculative scenarios around ~$2B; treat as market chatter and see linked sources.

• United Therapeutics advances Tyvaso for idiopathic pulmonary fibrosis after second phase 3 success

  United Therapeutics is preparing to expand the use of its marketed pulmonary arterial hypertension drug Tyvaso into idiopathic pulmonary fibrosis (IPF) following a second positive phase 3 trial. The company is outlining plans to file with the FDA, bolstered by the repeat success in this lung disease indication.

• United Therapeutics advances Tyvaso for idiopathic pulmonary fibrosis after second phase 3 success; Amgen gains EU nod for lung cancer BiTE

  United Therapeutics is preparing an FDA filing to expand Tyvaso's use following a second positive phase 3 trial in idiopathic pulmonary fibrosis (IPF), reinforcing its potential beyond pulmonary arterial hypertension.

• Kailera Therapeutics files for IPO to advance obesity drug pipeline

  Kailera Therapeutics, a biotech focused on obesity treatments, is advancing its late-stage drug candidates through a planned IPO in the US. After raising $1 billion in venture capital in 2025, the company seeks additional funding to accelerate clinical trials and development of its obesity drug portfolio. Led by Ron Renaud, Kailera aims to compete with established obesity drugs such as Wegovy and Zepbound, addressing a significant unmet medical need in the growing obesity market.

• AstraZeneca’s tozorakimab shows strong phase 3 results in COPD trials

  AstraZeneca’s tozorakimab, an IL-33 targeting drug for COPD, delivered unexpectedly strong phase 3 trial results, outperforming similar therapies that have struggled in this indication. The drug showed broad efficacy across COPD patient groups, suggesting it could address a significant unmet need beyond the reach of current treatments such as Dupixent. This breakthrough may reinvigorate the COPD drug class and pave the way for regulatory approvals and wider patient access.

• Novartis acquires Excellergy in $2 billion deal to develop next-gen allergy drug

  Novartis has entered a deal worth up to $2 billion to acquire Excellergy, a biotech developing a next-generation anti-IgE therapy.

• FDA approves Rocket's gene therapy Kresladi for rare immune disorder

  Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi (marnetegragene autotemcel), its first hematopoietic stem cell-based gene therapy, to treat children with severe leukocyte adhesion deficiency-1 (LAD-1).

• FDA clears Denali's Avlayah for Hunter syndrome, marking progress for rare disease treatments

  The FDA has approved Denali Therapeutics' drug Avlayah for Hunter syndrome, a rare genetic disorder. This approval is seen as a significant advancement following previous regulatory delays and rejections affecting rare disease therapies.

• FDA approves Denali Therapeutics’ enzyme therapy for Hunter syndrome, breaking rare disease rejection streak

  Denali Therapeutics has received FDA approval for Avlayah, an enzyme replacement therapy targeting Hunter syndrome, a rare genetic lysosomal storage disorder. This approval ends a recent pattern of FDA rejections for rare disease therapies, which had drawn criticism from the biotech community. Industry observers describe Avlayah as a 'game-changer' that could improve treatment options for patients with this debilitating condition and reinvigorate confidence in rare disease drug development.

• FDA approves Corcept’s first-in-class drug Lifyorli for platinum-resistant ovarian cancer

  The FDA has approved Corcept Therapeutics' Lifyorli (relacorilant) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three prior systemic treatments, including at least one with bevacizumab....

• Takeda plans major restructuring to fund drug launches and pipeline development

  Takeda is initiating a sweeping restructuring plan targeting $1.2 billion in cost savings through 2028 to finance upcoming drug launches and late-stage pipeline development. This strategic move under the new CEO focuses on operational streamlining and will involve substantial workforce reductions, particularly affecting the Cambridge, Massachusetts site and remote employees. The restructuring underscores Takeda's efforts to optimize resources for its future growth in pharmaceuticals.

• Maze Therapeutics posts positive phase 2 data for kidney disease drug amid mixed investor reactions

  Maze Therapeutics announced topline phase 2 results for its lead candidate targeting APOL1-mediated kidney disease, with analysts praising its best-in-class potential. However, some investors expressed caution due to competition from Vertex's genetically-driven kidney disease drug, leading to a notable stock decline.

• Merck to acquire Terns Pharmaceuticals for $6.7 billion to gain promising leukemia drug

  Merck's $6.7 billion all-cash acquisition of Terns Pharmaceuticals centers on a differentiated chronic myeloid leukemia treatment that could rival Novartis' Scemblix. The deal, reported as nearing completion, reflects Merck's strategic focus on oncology and hematology therapies. Analysts suggest the modest premium paid may attract competing offers, indicating high market interest in this promising asset. This acquisition exemplifies ongoing consolidation and investment in biotech innovation targeting leukemia.

• Gilead acquires Ouro Medicines for $2.2 billion to advance bispecific antibodies in autoimmune disease

  Gilead Sciences has acquired Ouro Medicines, a biotech company launched last year, in a deal valued at $2.2 billion.

• MSD partners with Quotient Therapeutics in $2.2 billion deal for IBD drug targets

  MSD has secured access to Quotient Therapeutics' somatic genomics platform through a $2.2 billion deal aimed at identifying novel drug targets for inflammatory bowel disease. This partnership highlights the growing role of genomics in drug discovery and MSD's strategic investment in innovative approaches to address significant unmet medical needs in IBD. The $20 million upfront payment signals immediate commitment to advancing this collaboration.

• Apogee Therapeutics' phase 2 data highlight potential blockbuster eczema drug

  Coverage discusses speculative scenarios around ~$5.2B; treat as market chatter and see linked sources.

• Pfizer and Valneva to seek approval for Lyme disease vaccine despite phase 3 trial missing primary endpoint

  Pfizer and Valneva reported that their phase 3 Lyme disease vaccine trial did not meet its primary endpoint, attributing the shortfall to fewer than expected Lyme disease cases during the study.

• Novartis commits $480 million to expand manufacturing and R&D in China

  Novartis is significantly increasing its footprint in China by investing more than 3.3 billion yuan (about $480 million) to upgrade its manufacturing site in Beijing and bolster its R&D campus in Shanghai, where its China headquarters are located. This move aligns with a broader industry trend of major pharma companies enhancing their manufacturing and research capabilities in China to better serve the local market and accelerate innovation.

• FDA schedules public hearing to gather input on national priority voucher program

  The FDA has announced a public hearing on June 12 to solicit industry feedback on its National Priority Voucher program, launched last June. The program has enabled four ultra-rapid drug reviews so far but has faced criticism for its lack of transparency.

• Sanofi pays $180 million for rights to Kali Therapeutics' phase 1 trispecific antibody

  Sanofi has re-entered the T-cell engager space by securing rights to a phase 1-stage trispecific antibody from Kali Therapeutics.

• Roche and Genentech halt development of muscle growth antibody for rare diseases

  Roche has stopped development of its experimental SMA drug emugrobart after it failed to consistently improve muscle growth and motor function in a key study.

• Novartis acquires Synnovation’s PI3Kα breast cancer drug in multi-billion dollar deal

  Novartis has acquired a unit of privately held Synnovation Therapeutics for up to $3 billion, securing a promising PI3Kα inhibitor aimed at treating breast cancers driven by PIK3CA mutations.

• FDA expands approval of Rhythm Pharma's Imcivree to acquired hypothalamic obesity

  Rhythm Pharma's Imcivree has received FDA approval for acquired hypothalamic obesity, marking the first drug approved for this brain injury-driven form of obesity.

• FDA grants priority voucher for higher-dose Wegovy, speeding Novo Nordisk's approval

  Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance to just 54 days.

• Lilly’s retatrutide shows strong results in type 2 diabetes and obesity trial

  Eli Lilly’s experimental triple agonist drug retatrutide demonstrated significant reductions in blood sugar and body weight in a large phase 3 trial involving patients with type 2 diabetes.

• Pfizer targets earlier use of Talzenna in prostate cancer after positive phase 3 results

  After the FDA declined approval for Talzenna in a broader metastatic castration-resistant prostate cancer setting, Pfizer is repositioning the PARP inhibitor for earlier use in metastatic hormone-sensitive prostate cancer. Positive phase 3 trial results support this shift, which may influence regulatory decisions and clinical guidelines. This move aims to improve patient outcomes and increase Talzenna's market viability following initially slow sales.

• AstraZeneca plans cell therapy manufacturing and innovation hub in Shanghai

  AstraZeneca announced plans to build a commercial cell therapy manufacturing base and an innovation center in Shanghai as part of its $15 billion investment commitment in China.

• J&J receives FDA approval for oral psoriasis drug icotyde

  Johnson & Johnson has secured FDA approval for Icotyde, an oral peptide drug targeting IL-23 for the treatment of psoriasis. This marks the first oral medication to block IL-23, a pathway targeted by leading injectable therapies like Skyrizi and Tremfya.

• Aspen Neuroscience reports positive one-year data for Parkinson’s stem cell therapy, plans phase 3 trial

  Aspen Neuroscience has shared promising data from its Phase 1/2 trial of a stem cell-derived therapy for Parkinson’s disease, showing symptom improvement in all eight treated patients after one year. Building on these positive results, the company is advancing plans for a pivotal Phase 3 trial scheduled for later in 2026. This development marks a significant step forward in the clinical advancement of cell therapies targeting neurodegenerative diseases.

• Biotechs Excalipoint and Crossbow secure major funding for T-cell engager development

  Chinese biotech Excalipoint raised $69 million to advance its portfolio of next-generation T-cell engagers, marking one of the largest drug startup fundraises in China.

• FDA issues draft guidance to advance alternatives to animal testing in drug development

  The FDA has released draft guidance to support drug developers in validating new approach methodologies (NAMs) as alternatives to animal testing.

• Bicycle Therapeutics cuts workforce and deprioritizes lead cancer drug amid regulatory delays

  Facing unexpected regulatory hurdles, Bicycle Therapeutics is scaling back operations by cutting roughly 30% of its staff and deprioritizing its lead bladder cancer drug candidate. This drug was positioned as a competitor to Pfizer’s Padcev, but the company now expects a longer path to approval, leading to a strategic shift away from this program.

• Pfizer’s atirmociclib shows positive phase 2 results in second-line metastatic breast cancer

  Pfizer announced positive phase 2 results for atirmociclib, a CDK4-selective inhibitor, in second-line ER+ metastatic breast cancer.

• US court blocks RFK Jr.'s changes to childhood vaccine policy as unlawful

  A federal court has ruled that Robert F. Kennedy Jr.'s attempts to alter the US childhood immunization schedule and overhaul a key CDC advisory panel were unlawful.

• R1 Therapeutics launches with $77.5 million to develop new treatment for hyperphosphatemia in chronic kidney disease

  R1 Therapeutics has emerged from stealth mode with an oversubscribed $77.5 million Series A financing to advance a first-in-class oral therapy targeting hyperphosphatemia in dialysis patients with chronic kidney disease (CKD).

• BioVie plans $19.7 million IPO for spinout developing liver disease treatment

  BioVie is initiating a $19.7 million IPO to fund a spinout dedicated to repurposing an existing low blood pressure medication for liver disease treatment. The spinout will focus on developing a new formulation of the approved drug, aiming to address unmet needs in liver disease therapeutics. This strategic step highlights BioVie's commitment to advancing drug development through targeted spinouts and capital raises.

• Structure Therapeutics reports best-in-class weight loss with oral GLP-1 candidate aleniglipron

  Structure Therapeutics announced that its oral GLP-1 drug candidate aleniglipron achieved a 16% weight loss in clinical testing, marking the highest efficacy reported for an oral GLP-1 treatment to date. The company is preparing to advance aleniglipron into phase 3 trials.

• GSK expands FDA approval for RSV vaccine Arexvy to younger adults at risk

  GSK has achieved a significant regulatory advancement with the FDA's expanded approval of its RSV vaccine Arexvy for younger adults aged 18 to 49 at increased risk of RSV-related lower respiratory tract disease. This approval places GSK on equal footing with Pfizer and Moderna, who previously secured FDA endorsements for their RSV vaccines. The broader clearance comes at a time when Arexvy's sales growth has plateaued, offering potential to boost uptake in a competitive and difficult vaccine market.

• Immutep's phase 3 failure shocks investors amid broader biotech layoffs

  Immutep, an Australian biotech company, faced an unexpected setback as its LAG-3 immunotherapy candidate failed in a phase 3 clinical trial, surprising analysts and causing a sharp decline in its stock.

• FDA restarts review of Capricor’s Duchenne cell therapy as Xenon reports strong epilepsy results

  Xenon Pharmaceuticals saw its shares surge nearly 50% after reporting epilepsy trial results that exceeded Wall Street expectations.

• BioNTech founders to leave and launch new next-generation mRNA company

  BioNTech CEO Uğur Şahin and CMO/co-founder Özlem Türeci plan to depart the company by the end of the year to start a new venture focused on next-generation mRNA innovations.

• FDA approves leucovorin for rare cerebral folate deficiency but not for autism

  The FDA has approved Wellcovorin (leucovorin calcium) tablets for treating cerebral folate deficiency in patients with a confirmed folate receptor 1 gene variant (CFD-FOLR1).

• The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug development by removing certain testing requirements for t...

  The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs.

• Bristol Myers claims success in study of another next-gen blood cancer drug

  Bristol Myers Squibb's mezigdomide has achieved a significant milestone in its phase 3 trial, showing improved progression-free survival for multiple myeloma patients. This drug is seen as a successor to existing treatments like Revlimid and Pomalyst.

• Roche's oral SERD flunks phase 3 breast cancer test

  Roche's giredestrant has failed to meet its primary endpoint in a phase 3 trial for first-line breast cancer, raising concerns about its efficacy in this treatment stage. This follows previous successes in adjuvant and second-line settings, marking a significant setback for the drug.

• Vinay Prasad, controversial FDA leader, to again depart agency

  Vinay Prasad, the controversial director of the FDA's Center for Biologics Evaluation and Research, is set to leave the agency at the end of April. His tenure has been characterized by significant changes to vaccine guidelines and contentious drug rejections, leading to criticism from various advocates.

• Servier to build cancer drug pipeline with $2.5B purchase of Day One

  Servier snaps up cancer biotech Day One in $2.5bn deal Phil.Taylor Fri, 06/03/2026 - 15:03.

• Roche and Zealand's obesity drug results disappoint

  The recent performance of Roche and Zealand's obesity drug has raised concerns among investors and analysts. The amylin-targeting medication, which is central to a multibillion-dollar partnership between the two companies, has shown less weight loss efficacy than anticipated, leading to questions about its market differentiation. This disappointing outcome has resulted in a decline in shares for both companies, as stakeholders reassess the drug's potential in a competitive landscape.

• FDA Commissioner Marty Makary, M.D., called J&J’s Tecvayli-Darzalex phase 3 showing the “most impressive second-line myeloma trial results in history.”

  J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.

• FDA Places Partial Hold on PepGen's Muscular Dystrophy Drug Trial

  The FDA has placed a partial clinical hold on PepGen's phase 2 trial for its muscular dystrophy drug, creating uncertainty in the drug's development timeline. Analysts attribute this unexpected pause to the agency's staffing challenges, raising concerns about the impact on ongoing clinical programs.

• FDA intensifies scrutiny of compounded GLP-1 drugs and novo nordisk ads

  The FDA has ramped up its crackdown on compounded GLP-1 drugs, issuing 30 warning letters to pharmacies. Novo Nordisk faces regulatory scrutiny over its GLP-1 ads, while Intellia is set to restart a heart disease trial.

• Sanofi acquires sino biopharm’s JAK/ROCK inhibitor for $1.53B

  Sanofi has made a significant move in the biotech sector by acquiring global rights to a first-in-class JAK/ROCK inhibitor from Sino Biopharmaceutical for $1.53 billion. This novel drug is expected to enhance Sanofi's offerings in both hematology and immunology, targeting conditions such as myelofibrosis and chronic graft-versus-host disease (cGVHD). The deal underscores Sanofi's commitment to expanding its pipeline with innovative therapies.

• Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roiva...

  Moderna agrees $950m settlement of mRNA jab litigation Phil.Taylor Wed, 04/03/2026 - 13:19.

• Biotech companies face layoffs after regulatory setbacks

  Disc Medicine and Theravance Biopharma are laying off employees due to recent regulatory challenges, reflecting the financial strain on biotech firms.

• UniQure faces major setback as FDA rejects gene therapy data package

  uniQure's AMT-130 gene therapy for Huntington's disease has encountered a significant regulatory hurdle as the FDA has rejected its data package. This decision has led to a dramatic 40% drop in the company's shares. The FDA now requires uniQure to conduct a new sham surgery-controlled trial before any approval can be considered, which could further delay access to this potential treatment for patients suffering from Huntington's disease.

• Ascendis wins FDA approval of dwarfism drug yuviwel

  Ascendis Pharma has achieved a significant milestone with the FDA's approval of Yuviwel, a once-weekly injection designed to treat children with achondroplasia, a genetic disorder leading to dwarfism. This marks the third FDA approval for the Copenhagen-based biopharma in six years, showcasing the effectiveness of its TransCon platform and transient conjugation drug delivery technology. Yuviwel is set to compete with BioMarin's established daily injection, Voxzogo, in the market for dwarfism treatments.

• Roche's fenebrutinib achieves phase 3 success amid safety concerns

  Roche's fenebrutinib has successfully met its primary endpoint in a second Phase 3 study for relapsing multiple sclerosis. However, the drug's approval may be jeopardized by safety concerns, including a higher mortality rate compared to the control group.

• Aardvark therapeutics halts key clinical trial over safety concerns

  Aardvark Therapeutics has paused a Phase 3 trial of its lead metabolic drug due to safety concerns related to cardiac issues, resulting in a significant drop in share price.

• Eli lilly partners with nvidia to innovate pharma with AI

  Eli Lilly's collaboration with Nvidia aims to innovate drug development using AI technology. However, experts express skepticism about AI's effectiveness in speeding up clinical trials, emphasizing the need for realistic expectations.

• While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with...

  Moderna closes on EU approval for combined flu/COVID jab Phil.Taylor Fri, 27/02/2026 - 12:52.

• Senate hearing critiques fda's rare disease review process

  In a recent Senate hearing, a panel comprising physicians, biotech leaders, and patient advocates criticized the FDA's processes, particularly regarding its impact on innovation in the field of rare diseases. The discussion highlighted concerns over the agency's bureaucracy and its implications for drug development and approval timelines. Lawmakers are increasingly pressing the FDA to improve its record on rare diseases, reflecting a growing urgency to enhance the regulatory environment for biotech advancements.

• Bristol myers squibb's ADC hits key survival endpoints in phase 3 trial

  Bristol Myers Squibb's ADC has achieved dual primary survival endpoints in a phase 3 breast cancer trial in China, validating its $800 million investment. The drug, in-licensed from Systimmune, is crucial for the company's future growth and is undergoing further trials in TNBC.

• Eli lilly's orforglipron outperforms competitors in diabetes trials

  Eli Lilly's orforglipron has outperformed Rybelsus and Wegovy in recent trials, showing significant weight loss and blood sugar reduction. This oral medication could provide a non-injection alternative for diabetes and obesity treatment.

• Surge in licensing deal values between western and chinese biopharma

  The landscape of biotech licensing deals between Western biopharma companies and their Chinese counterparts has undergone a significant transformation. Recent data reveals that the average upfront value for these deals has surged dramatically, reflecting a shift in the market dynamics.

• Fierce Pharma: 15 States sue HHS over changes to childhood vaccine schedule

  A coalition of 15 states has initiated legal action against the U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). The lawsuit aims to reverse recent changes to the childhood vaccine schedule, which the states argue were made unlawfully. The abrupt overhaul of the immunization schedule has raised concerns among these states, prompting them to challenge the federal government's actions in court.

• Slate medicines emerges with $130M to develop migraine drug

  Slate Medicines has launched with $130 million in funding to develop a novel injectable drug targeting PACAP for migraine prevention, addressing challenges faced by major competitors like Eli Lilly and Amgen.

• FDA unveils guidance for personalized therapies in rare diseases

  The FDA has introduced draft guidance to accelerate the development of personalized therapies for rare diseases and has outlined a new regulatory pathway for ultra-rare diseases, aiming to improve treatment accessibility for patients.

• FDA unveils draft guidance for personalized therapies in ultra-rare diseases

  The FDA has recently unveiled a series of draft guidance documents aimed at accelerating the development and approval of personalized therapies for ultra-rare diseases. This initiative is part of a broader effort to provide a regulatory framework that supports the creation of individualized treatments, particularly when traditional randomized controlled trials are not feasible due to limited patient populations.

• Novo’s next-gen obesity shot fails to match lilly drug in head-to-head study

  Novo Nordisk's latest obesity treatment, CagriSema, has faced significant setbacks in clinical trials, failing to outperform Eli Lilly's Zepbound in a head-to-head study. This disappointing outcome has led to a sharp decline in Novo Nordisk's stock price, reflecting investor concerns about the future of its obesity drug portfolio.

• FDA unveils new approval pathways for personalized therapies

  The FDA has introduced draft guidance to accelerate the approval of individualized therapies for ultra-rare diseases and bespoke gene therapies, including CRISPR treatments. This initiative aims to streamline the development process and enhance access to innovative therapies.

• Gilead buys cell therapy partner arcellx for up to $7.8bn

  Gilead has acquired Arcellx for up to $7.8 billion, aiming to enhance its cell therapy portfolio, particularly for multiple myeloma. This acquisition focuses on a CAR-T cell therapy that is nearing regulatory approval, which Gilead's CEO believes will become a foundational treatment for this type of blood cancer. The move is seen as a strategic effort to revitalize Gilead's cell therapy business amid a competitive landscape.